Nano-aggregates: emerging delivery tools for tumor therapy

Area of Science:

• Nanotechnology
• Materials Science
• Oncology

Background:

• Site-specific drug delivery is crucial for effective cancer therapy, especially for poorly soluble drugs.
• Conventional formulations often struggle with low bioavailability and off-target toxicity.
• Nano-aggregates represent a novel class of supramolecular colloidal carriers for advanced drug delivery systems.

Purpose of the Study:

• To review the synthesis and tumor targeting potential of nano-aggregates for anticancer drug delivery.
• To explore both passive and active targeting strategies employed by nano-aggregates.
• To discuss the characterization, preclinical, and clinical evaluation of nano-aggregate drug delivery systems.

Main Methods:

• Formation of nano-aggregates from polymer-drug conjugated amphiphilic block copolymers.
• Encapsulation of poorly water-soluble drugs via covalent conjugation or physical encapsulation.
• Active targeting achieved by conjugating nano-aggregates with tumor-specific ligands or vectors.
• Passive targeting leveraging the enhanced permeability and retention (EPR) effect.

Main Results:

• Nano-aggregates exhibit desirable properties including nanometer size, high loading efficiency, and in vivo stability.
• Physical encapsulation allows for maximum drug loading, increasing drug concentration at the target site.
• Active targeting strategies demonstrate specific binding to overexpressed tumor cell receptors.
• Review covers characterization, ex vivo studies, biodistribution, clinical trials, and patents.

Conclusions:

• Nano-aggregates are a versatile and effective platform for site-specific delivery of anticancer drugs, particularly those with poor water solubility.
• Both passive and active targeting mechanisms enhance therapeutic efficacy and minimize systemic toxicity.
• Further research and clinical translation of nano-aggregates hold significant promise for molecular targeted cancer therapies.